• Nasodine Nasal Spray launched in Singapore, with online and retail pharmacy sales
• US online sales growing, but limited by regulatory constraints
• New licensing deal signed for Fiji and South Pacific
• Funding required to support ongoing operations and expansion

Firebrick Pharma Ltd reported its financial results for the half-year ended 31 December 2024, with the key highlights being the launch of Nasodine Nasal Spray in Singapore and continued growth in the US online market. The company received an R&D Tax Incentive payment of $919,656 during the period, which was already recognized in the previous financial year, leading to a reported net loss of $1.45 million, up 61% from the prior corresponding period. However, adjusting for the timing of the R&D tax credit, the underlying operating loss was $526,722. The company's focus has shifted from R&D to commercialization, with marketing and business development costs increasing while R&D expenses declined. In Singapore, Nasodine was launched through online sales, followed by a partnership with the Guardian pharmacy chain, the largest in the country. The company also started promoting Nasodine to healthcare professionals in Singapore, with a positive initial response. In the US, Nasodine was launched as a nasal cleanser, limiting the marketing claims, but online sales have shown solid growth. The company expects to launch Nasodine in the Philippines in 2026 through a licensing partnership. Firebrick also announced a new licensing deal for Fiji and the South Pacific. The company will require additional funding to support its ongoing operations and international expansion plans.

Firebrick expects to see significant sales growth in Singapore as consumer and healthcare professional adoption of Nasodine increases during 2025. The company is also exploring new licensing deals in other countries, which could lead to further international launches of Nasodine in the coming years.